enGene Therapeutics Inc. (ENGN) intrinsic value & 10-year financials
enGene Therapeutics Inc. (ENGN) has a Graham intrinsic value of $48.40 per share. At $1.67 on Oct 17, 2026, the stock trades 97% below that value.
- Graham intrinsic value
- $48.40
- Share price (Oct 17, 2026)
- $1.67
- Price vs Graham value
- 97% below
- Market cap
- $85.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 280.3%
- Free cash flow (FY2025)
- -$100.7M
ENGN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$117.3M | $2.29 | -$100.7M | — | -109.5% |
| FY2024 | — | -$55.1M | $1.46 | -$49.2M | — | -61.6% |
| FY2023 | — | -$99.9M | $2.75 | -$25.1M | — | 1262.6% |
| FY2022 | — | -$24.5M | $0.81 | -$17.7M | — | 29.9% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
enGene Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
enGene Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -32.1% ROIC.
enGene Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, enGene Therapeutics Inc. is modeled at 8.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $48.40 per share.